OverviewSuggest Edit

Amicus Therapeutics is a biopharmaceutical company developing oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. The Company is focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. Its technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded, unstable proteins caused by genetic mutations. It is initially targeting lysosomal storage disorders and continues to develop its pharmacological chaperone technology having built an intellectual property portfolio along with its robust clinical and preclinical pipeline.

TypePublic
Founded2002
HQCranbury Township, US
Websiteamicusrx.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Feb 2019)400(+24%)
Job Openings31
Revenue (FY, 2017)$36.9 M(+645%)
Share Price (Mar 2019)$13.3 (-4%)

Key People/Management at Amicus Therapeutics

William D. Chip Baird

William D. Chip Baird

CFO
Bradley L Campbe

Bradley L Campbe

COO
Jeffrey P Castelli

Jeffrey P Castelli

Vp
Enrique Diloné

Enrique Diloné

Vp
Jay A Barth

Jay A Barth

Chief Medical Officer
Hung Do

Hung Do

Senior Vice President
Show more

Amicus Therapeutics Office Locations

Amicus Therapeutics has offices in Cranbury Township, Milano, München, Pointe-Claire and in 6 other locations
Cranbury Township, US (HQ)
1 Cedarbrook Dr, Cranbury
Northbridge, AU
21 Dorset Rd
Pointe-Claire, CA
6500 TransCanada Service Rd, 4th Floor
Puteaux, FR
Tour Défense 2000
München, DE
Willy-Brandt-Platz
Milano, IT
5° Floor, Via Giovanni Boccaccio, 11
Show all (10)
Report incorrect company information

Amicus Therapeutics Financials and Metrics

Amicus Therapeutics Revenue

Amicus Therapeutics's revenue was reported to be $36.93 m in FY, 2017
USD

EBIT (FY, 2018)

(328.8m)

Market capitalization (22-Mar-2019)

3.0b

Closing stock price (22-Mar-2019)

13.3

Cash (31-Dec-2018)

79.7m
Amicus Therapeutics's current market capitalization is $3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

363.0k1.2m5.0m36.9m

Revenue growth, %

(99%)(100%)

Cost of goods sold

833.0k6.2m

Gross profit

4.1m30.7m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Revenue

39.0k456.0k475.0k293.0k456.0k475.0k293.0k

Cost of goods sold

344.0k775.0k1.8m

General and administrative expense

4.6m5.2m4.8m5.3m6.4m8.3m15.4m15.7m19.3m17.5m19.1m21.6m

R&D expense

10.1m10.0m10.0m12.0m16.1m17.2m21.0m23.4m18.3m32.5m30.9m40.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

43.6m24.1m69.5m187.0m49.1m79.7m

Accounts Receivable

1.3m9.5m22.0m

Inventories

5.5m2.9m2.6m3.4m4.6m8.4m

Current Assets

88.3m154.6m216.6m340.1m392.0m551.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

30.0m27.5m41.9m19.7m28.8m249.0m19.4m23.5m63.7m33.1m44.8m37.4m64.1m114.3m73.3m201.8m

Accounts Receivable

864.0k1.9m3.8m6.0m10.8m15.1m14.2m

Inventories

194.0k3.3m3.7m3.9m7.3m8.1m7.8m6.3m

Current Assets

64.3m73.5m79.4m87.2m151.3m365.0m240.1m168.5m217.7m221.7m296.2m241.0m431.0m592.0m576.2m601.0m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(59.6m)(68.9m)(132.1m)(200.0m)(284.0m)(349.0m)

Depreciation and Amortization

1.7m1.5m1.8m3.2m3.6m4.2m

Inventories

(3.2m)2.3m308.0k(3.7m)(897.0k)(4.2m)

Accounts Payable

6.2m15.5m7.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(47.4m)(15.9m)(30.6m)(47.7m)(24.3m)(51.4m)(89.2m)(43.7m)(94.7m)(141.4m)(55.0m)(103.1m)(214.8m)(49.9m)(111.8m)(270.9m)

Depreciation and Amortization

1.3m412.0k808.0k1.2m508.0k861.0k1.3m673.0k1.4m2.3m823.0k1.6m2.5m969.0k1.9m3.0m

Inventories

(207.0k)(3.5m)(243.0k)(351.0k)(3.4m)(3.3m)(3.4m)(2.0m)

Accounts Payable

(679.0k)(987.0k)(155.0k)1.2m(551.0k)459.0k14.1m(9.8m)(8.2m)(2.9m)(1.3m)
USDY, 2018

Financial Leverage

2.3 x
Show all financial metrics
Report incorrect company information

Amicus Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Amicus Therapeutics News and Updates

Amicus Therapeutics Announces Full-Year 2018 Financial Results and 2019 Corporate Updates

Continued Strong Galafold Launch Trends in Early 2019 - On Track to Achieve FY19 Revenue Guidance of $160M-$180M

Amicus Therapeutics Announces Presentations and Posters at 15th Annual WORLDSymposium™ 2019

CRANBURY, N.J., Jan. 18, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced that four oral presentations and eight posters highlighting its develo…

Amicus Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference

CRANBURY, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Credit Suisse 27th Annual Healthcare Conference in Scottsdale, Arizona on Wednesday, November 14…

Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates

U.S. Galafold ® (Migalastat) Fabry Launch Tracking Significantly Ahead of Expectations- 100+ Patients Prescribed Galafold Since August Launch

Amicus Therapeutics to Announce Third Quarter 2018 Financial Results on November 5, 2018

CRANBURY, N.J., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 5, 2018 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2018.

Amicus Therapeutics Announces Positive 18-Month Data in Pompe Disease Phase 1/2 Study at 23rd International Annual Congress of the World Muscle Society

Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Continue Out to Month 18 for both ERT-Naïve and ERT-Switch Patients
Show more
Report incorrect company information

Amicus Therapeutics Blogs

Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia

Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia Content Import Tue, 02/26/2019 - 07:05 Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia Feb 26, 2019 This release is a backfill fro…

Amicus Therapeutics to Announce Full-Year 2018 Financial Results on February 28, 2019

CRANBURY, N.J. , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 28, 2019 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2018 .

Amicus Therapeutics Announces Positive data in Pompe Disease Phase 1/2 Study for Up to 24 Months at 15th Annual WORLDSymposium™

Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Continue for both ERT-Naïve and ERT-Switch Patients Patient Reported Outcomes Data Demonstrate Benefits in Activities of Daily Living and Patient Well Being for AT-GAA Treated Patients Detailed

Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance

Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance Content Import Mon, 01/07/2019 - 07:06 Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance Jan 7, 2019 This release is a backfill from a News …

Amicus Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 37 th  Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 8,

Amicus Therapeutics Announces Phase 1/2 Study of Gene Therapy for CLN3 Batten Disease

Second Gene Therapy to Enter Clinic at Nationwide Children’s Hospital for Neurologic Lysosomal Storage Disorders Initial Safety is Encouraging with No Serious Adverse Events at One Month CRANBURY, N.J. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology
Show more

Amicus Therapeutics Frequently Asked Questions

  • When was Amicus Therapeutics founded?

    Amicus Therapeutics was founded in 2002.

  • Who are Amicus Therapeutics key executives?

    Amicus Therapeutics's key executives are William D. Chip Baird, Bradley L Campbe and Jeffrey P Castelli.

  • How many employees does Amicus Therapeutics have?

    Amicus Therapeutics has 400 employees.

  • Who are Amicus Therapeutics competitors?

    Competitors of Amicus Therapeutics include PhaseBio Pharmaceuticals, Sanofi Genzyme and Recro Pharma.

  • Where is Amicus Therapeutics headquarters?

    Amicus Therapeutics headquarters is located at 1 Cedarbrook Dr, Cranbury, Cranbury Township.

  • Where are Amicus Therapeutics offices?

    Amicus Therapeutics has offices in Cranbury Township, Milano, München, Pointe-Claire and in 6 other locations.

  • How many offices does Amicus Therapeutics have?

    Amicus Therapeutics has 10 offices.